Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 8 pages · English
Earlier from Acrux
- FDA clears regulatory pathway for Female Testosterone MDTS
- Webinar, Monday 12 October 2026 - Female Testosterone MDTS
- Acrux has received $1.977m RDTI rebate for FY26
- Application for quotation of securities - ACR
- AGM date, closing date for director nominations
Later from Acrux
- Notice of Annual General Meeting/Proxy Form
- Notification of cessation of securities - ACR
- Company Secretary/CFO Appointment/Resignation
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux